DMEMEDS shared post via Reuters: U.S. health insurers say Gilead hepatitis C drug too costly

(Reuters) - The leading U.S. health insurance trade group on Tuesday hit out at the extremely high cost of new specialty medicines, accusing drugmakers of taking advantage of the insurance system by pricing products at unsustainable levels. [Category: healthNews] http://feeds.reuters.com/~r/reuters/healthNews/~3/1yORwnZ-RlE/story01.htm

Read More